Dr Eleni Efstathiou (MD Anderson Cancer Center, Houston, USA) chairs a virtual discussion with Prof Álvaro Pinto (La Paz University Hospital, Madrid, Spain), Prof Nicolas Mottet (University Hospital St Etienne, St Etienne, France) and Prof Heather Payne (University College Hospital, London, UK) about the latest EAU guidelines for treating patients with advanced prostate cancer.

Prof Payne outlines the how the use of androgen signalling inhibitors in hormone-sensitive metastatic prostate cancer ties in with the current EAU guidelines and in her everyday practice. Prof Payne also references the results from TITAN and ENZAMET trials that support the use of enzalutamide and apalutamide in these patients.

Prof Mottet explains that the combination of enzalutamide and apalutamide is not recommended currently, as reflected the guidelines.

Prof Pinto suggests that de novo metastatic and patients with recurrent disease may be different, which could be due to a different molecular profile or access to diagnostic procedures. He also states there is a lack of trials designed specifically for recurrent patients.

The panel conclude by discussing the impact of the latest EAU guidelines, which Prof Mottet states are multidisciplinary.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).